Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 14.05.2026 FTFX IE00BD5HBQ97   63,402.00 USD   1,691,529.99   26.679  ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to present 8 abstracts on affordability, access and adoption across women’s health, biosimilar and general medicines portfolio at ISPOR 2026....

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced the closing of two previously announced financing transactions: a private offering of $500 million in aggregate principal amount of 5.75% senior notes due 2034, and an amendment to the Company's existing credit agreement (the "Amendment"), which extends the maturity of the Company's Term Loan B facility to 2033 and upsizes and extends the Company's revolving credit facility to $1.0 b...

VICTORIA, British Columbia--(BUSINESS WIRE)--Vecima will highlight its leadership in next-generation Fiber Access at Fiber Connect 2026 showcasing products from its Entra All-PON portfolio....

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 was transformational for the Company, with the acquisition of Faeth Therapeutics and the concurrent $200 million private placement in February, supported by a group of leading life sciences investors,” said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics. “This ac...

DAYTON, Ohio--(BUSINESS WIRE)--REX American Resources Corporation (“REX” or the “Company”) (NYSE: REX), a leading ethanol production company, announced today that it will report its fiscal first quarter 2026 operational and financial results on Thursday, May 28th, 2026 pre-market and will host a conference call and webcast at 11:00 a.m. ET that morning to review the results. To access the conference call, interested parties may dial (877) 269-7751 (US) or (201) 389-0908 (international). Partici...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Hauptsitz in Tokio; President und Representative Director: Toshiaki Nagasato) gab heute bekannt, dass die Ergebnisse der Integral-1-Studie, einer von zwei globalen klinischen Phase-III-Studien zur Bewertung der Wirksamkeit und Sicherheit des neuartigen β-Lactamase-Hemmers Nacubactam (Tntwicklungscode: OP0595), in The Lancet veröffentlicht wurden. Der Artikel lautet „Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared...

LONDON--(BUSINESS WIRE)--Endava, the technology-driven business transformation group whose AI-native approach combines cutting-edge technology with deep industry expertise today announced a strategic partnership with Tyl by NatWest, NatWest Group’s merchant-payments arm, to accelerate the evolution of its offering. The partnership is focused on enabling Tyl’s customers to access a modern, fully integrated payments acceptance experience. By combining Endava's global operations and its AI-native...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - March 14.05.2026 MMAR.LN IE0002PPCMH6   50,002.00 USD   1,326,609.29   26.531  ...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (oficinas centrales: Tokio; presidente y director representante: Toshiaki Nagasato) anunció hoy que los resultados del estudio Integral-1, uno de dos ensayos clínicos de fase 3 globales que evalúan la eficacia y la seguridad de nacubactam (código de desarrollo: OP0595), su nuevo inhibidor de β-lactamasa, fueron publicados en The Lancet. El artículo se titula “Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with im...